Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

FDA approves new pulmonary artery sensor for heart failure

Endotronix, an Illinois-based healthcare technology company, has gained U.S. Food and Drug Administration approval for its Cordella Pulmonary Artery (PA) Sensor System, which uses PA pressure-guided therapy to manage and treat heart failure patients.

The Endotronix Cordella Pulmonary Artery (PA) Sensor System, which uses PA pressure-guided therapy to manage and treat heart failure patients. 

The Cordella platform from Endotronix includes an implantable sensor that tracks the patient’s PA pressure and other helpful health data.

  • Read more about FDA approves new pulmonary artery sensor for heart failure

Semaglutide improves heart failure symptoms in both sexes—weight loss greater in women

“Understanding the sex differences in obesity-related HFpEF is of great importance,” one cardiologist explained. “Obesity and visceral adiposity are key drivers of HFpEF development and progression, and this may be even more amplified in women."

  • Read more about Semaglutide improves heart failure symptoms in both sexes—weight loss greater in women

A cardiologist's guide to treating pulmonary embolism

Video interview with Peter Monteleone, MD, explaining the primary catheter-based interventional tools used to treat pulmonary embolism (PE). What are the interventional therapies for pulmonary embolism? Emerging Interventional Therapies for Pulmonary Embolism

Interventional cardiologist Peter Monteleone, MD, discussed the primary tools used to treat pulmonary embolism in the cath lab.

  • Read more about A cardiologist's guide to treating pulmonary embolism

New 5:2 intermittent fasting diet bests metformin, empagliflozin in patients with early-stage type 2 diabetes

5:2 intermittent fasting diet

The new-look diet was linked to significant weight loss and reductions in HbA1C levels. Researchers see it as a potential alternative to immediately putting patients on new medications. 

  • Read more about New 5:2 intermittent fasting diet bests metformin, empagliflozin in patients with early-stage type 2 diabetes

Heart surgeons are fed up with old technology—many have considered a career change

The Anesthesia Patient Safety Foundation (APSF), a related organization of the American Society of Anesthesiologists (ASA), this week released a statement on the criminalization of medical errors. The APSF said criminal prosecution is unjust and counterproductive is healthcare organizations want to find ways to mitigate errors by understanding how they happen and create protocols or IT systems can can help prevent future errors. The criminal trial of nurse RaDonda Vaught was counterproductive to safety.

A majority of U.S. surgeons, including those who treat heart patients on a daily basis, say their operating rooms use outdated technology. It is having a negative impact on patient care. 

  • Read more about Heart surgeons are fed up with old technology—many have considered a career change

Risk of death from CVD skyrockets when women use cannabis

cannabis use disorder marijuana joint weed smoking

“While the use of cannabis continues to gain popularity, its broader effects on public health within the general population are not yet fully understood,” one researcher said.

  • Read more about Risk of death from CVD skyrockets when women use cannabis

The future of electrophysiology: Reviewing key trends in PFA

Vivek Reddy, MD, Director, Cardiac Arrhythmia Service, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology, at Mount Sinai in New York, was involved in most of the late-breaking pulsed field ablation (PFA) trials at the Heart Rhythm Society (HRS) 2024 meeting. He offers an overview of the new data presented and his observations from using PFA. #HRS24 #HRS2024 #PFA #EPeeps

Vivek Reddy, MD, was involved in most of the late-breaking pulsed field ablation trials at Heart Rhythm 2024. He spoke to Cardiovascular Business at the conference about those trials and what they mean going forward.

  • Read more about The future of electrophysiology: Reviewing key trends in PFA

AI can help cardiologists predict death after TAVR—but there is a catch

artificial intelligence in cardiology

It's clear that advanced AI algorithms will radically transform care for TAVR patients in the years ahead. For now, however, certain AI models may require too much data to be helpful on a consistent basis. 

  • Read more about AI can help cardiologists predict death after TAVR—but there is a catch

FDA clears new drug-eluting envelope for implantable cardiac devices—CEO sees it as ‘tip of the iceberg’

Elutia, a Maryland-based healthcare technology company, has received clearance from the U.S. Food and Drug Administration (FDA) for EluPro, its new biologic envelope specifically designed for patients with implantable pacemakers and defibrillators. It was also cleared for use when implanting other types of devices, including neurostimulators and neuromodulators.

Elutia, formerly known as Aziyo Biologics, is already targeting additional uses for the newly approved device. 

  • Read more about FDA clears new drug-eluting envelope for implantable cardiac devices—CEO sees it as ‘tip of the iceberg’

The waiting game: Delaying TAVR increases healthcare costs by $10K per year

Delaying TAVR in eligible patients with severe AS can lead to much higher healthcare costs, according to a new study of real-world Medicare data.

  • Read more about The waiting game: Delaying TAVR increases healthcare costs by $10K per year

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …214
    • Page 215
    • Page 216
    • Page 217
    • Current page 218
    • Page 219
    • Page 220
    • Page 221
    • Page 222 …
    • Next page Next ›
    • Last page Last »
Subscribe
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme